Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic

D. Zemánek, J. Januška, T. Honěk, K. Čurila, M. Kubánek, Š. Šindelářová, L. Zahálková, P. Klofáč, E. Laštůvková, E. Lichnerová, R. Aiglová, J. Lhotský, J. Vondrák, G. Dostálová, M. Táborský, D. Kasper, A. Linhart

. 2022 ; 9 (6) : 4160-4166. [pub] 20220910

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032436

AIMS: Fabry disease (FD) is a rare X-linked genetic disorder caused by α-galactosidase A (AGALA) deficiency. Whereas 'classic' variant has multisystemic manifestation, the more recently described 'later-onset' variant is characterized by predominant cardiac involvement that often mimics hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: Consecutive unrelated patients with HCM were screened for FD in 16 (out of 17) cardiac centres in the Czech Republic covering specialized cardiology care from June 2017 to December 2018. AGALA activity and globotriaosylsphingosine (lyso-Gb3 ) levels were measured in all subjects using the dry blood spot method. FD was suspected in male patients with AGALA activity <1.2 μmol/h/L and in females with either low AGALA activity or lyso-Gb3 > 3.5 ng/mL. Positive screening results were confirmed by genetic testing. We evaluated 589 patients (390 males, 66%) with HCM (mean maximal myocardial thickness 19.1 ± 4.3 mm). The average age was 58.4 ± 14.7 years. In total, 17 patients (11 males, 6 females) had a positive screening result, and subsequently, six of them (four males and two females) had a genetically confirmed pathogenic GLA mutation (total prevalence of 1.02%). Five of these patients were carrying the p.N215S mutation known to cause a typical later-onset cardiac FD. CONCLUSIONS: We confirmed the prevalence of FD repeatedly reported in previous screening programmes (approximately 1% irrespective of gender) in a non-selected HCM population in Central Europe. Our findings advocate a routine screening for FD in all adult patients with HCM phenotype including both genders. The dry blood spot method used led to identification of clearly pathogenic variants.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032436
003      
CZ-PrNML
005      
20230131151748.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ehf2.14135 $2 doi
035    __
$a (PubMed)36087038
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Zemánek, David $u 2nd Department of Internal Medicine Cardiology and Angiology, General University Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic
245    10
$a Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic / $c D. Zemánek, J. Januška, T. Honěk, K. Čurila, M. Kubánek, Š. Šindelářová, L. Zahálková, P. Klofáč, E. Laštůvková, E. Lichnerová, R. Aiglová, J. Lhotský, J. Vondrák, G. Dostálová, M. Táborský, D. Kasper, A. Linhart
520    9_
$a AIMS: Fabry disease (FD) is a rare X-linked genetic disorder caused by α-galactosidase A (AGALA) deficiency. Whereas 'classic' variant has multisystemic manifestation, the more recently described 'later-onset' variant is characterized by predominant cardiac involvement that often mimics hypertrophic cardiomyopathy (HCM). METHODS AND RESULTS: Consecutive unrelated patients with HCM were screened for FD in 16 (out of 17) cardiac centres in the Czech Republic covering specialized cardiology care from June 2017 to December 2018. AGALA activity and globotriaosylsphingosine (lyso-Gb3 ) levels were measured in all subjects using the dry blood spot method. FD was suspected in male patients with AGALA activity <1.2 μmol/h/L and in females with either low AGALA activity or lyso-Gb3 > 3.5 ng/mL. Positive screening results were confirmed by genetic testing. We evaluated 589 patients (390 males, 66%) with HCM (mean maximal myocardial thickness 19.1 ± 4.3 mm). The average age was 58.4 ± 14.7 years. In total, 17 patients (11 males, 6 females) had a positive screening result, and subsequently, six of them (four males and two females) had a genetically confirmed pathogenic GLA mutation (total prevalence of 1.02%). Five of these patients were carrying the p.N215S mutation known to cause a typical later-onset cardiac FD. CONCLUSIONS: We confirmed the prevalence of FD repeatedly reported in previous screening programmes (approximately 1% irrespective of gender) in a non-selected HCM population in Central Europe. Our findings advocate a routine screening for FD in all adult patients with HCM phenotype including both genders. The dry blood spot method used led to identification of clearly pathogenic variants.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a alfa-galaktosidasa $x genetika $7 D000519
650    12
$a hypertrofická kardiomyopatie $x diagnóza $x epidemiologie $x genetika $7 D002312
650    12
$a Fabryho nemoc $x diagnóza $x epidemiologie $x genetika $7 D000795
650    _2
$a genetické testování $7 D005820
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Januška, Jaroslav $u Cardiocentre Podlesí, Třinec, Czech Republic
700    1_
$a Honěk, Tomáš $u 1st Department of Internal Medicine - Cardioangiology, St Anne's University Hospital and Masaryk University, Brno, Czech Republic
700    1_
$a Čurila, Karol $u Department of Cardiology, 3rd Faculty of Medicine, Charles University and University Hospital Kralovské Vinohrady, Prague, Czech Republic
700    1_
$a Kubánek, Miloš $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Šindelářová, Štěpánka $u Department of Cardiology, Hospital České Budějovice, České Budějovice, Czech Republic
700    1_
$a Zahálková, Lucie $u 1st Department of Medicine - Cardioangiology, Charles University Faculty of Medicine and University Hospital, Hradec Králové, Czech Republic
700    1_
$a Klofáč, Petr $u Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic
700    1_
$a Laštůvková, Eliška $u Department of Cardiology, Hospital Jihlava, Jihlava, Czech Republic
700    1_
$a Lichnerová, Eva $u Department of Cardiovascular Disease, University Hospital in Ostrava, Ostrava, Czech Republic
700    1_
$a Aiglová, Renata $u Department of Internal Medicine I - Cardiology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Lhotský, Jan $u Department of Cardiology, University Hospital and Faculty of Medicine Pilsen, Charles University, Prague, Czech Republic
700    1_
$a Vondrák, Jiří $u Department of Cardiology, Regional Hospital Pardubice and Faculty of Health Studies, University of Pardubice, Pardubice, Czech Republic
700    1_
$a Dostálová, Gabriela $u 2nd Department of Internal Medicine Cardiology and Angiology, General University Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic
700    1_
$a Táborský, Miloš $u Department of Internal Medicine I - Cardiology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Kasper, David $u ARCHIMED Life Science GmbH, Vienna, Austria
700    1_
$a Linhart, Aleš $u 2nd Department of Internal Medicine Cardiology and Angiology, General University Hospital and 1st Faculty of Medicine of Charles University, Prague, Czech Republic $1 https://orcid.org/0000000233727850
773    0_
$w MED00197251 $t ESC heart failure $x 2055-5822 $g Roč. 9, č. 6 (2022), s. 4160-4166
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36087038 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151744 $b ABA008
999    __
$a ok $b bmc $g 1891285 $s 1183771
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 9 $c 6 $d 4160-4166 $e 20220910 $i 2055-5822 $m ESC heart failure $n ESC Heart Fail $x MED00197251
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace